No Data
No Data
Sano Medical Science & Technology Co., Ltd. Third Quarter Report 2024
sino medical sciences technology inc. (688108): Deeply cultivating the vascular intervention field for more than ten years, innovation is expected to bring harvest.
Shenjie, dual-track driven coronary artery molding, innovative medical devices moving towards globalization. Sino Medical Sciences Technology Inc. was established in 2007, the core team focusing on high-value intervention devices field for over 15 years, forming a dual-track drive in neurointervention and cardiovascular coronary artery business, drug elution
Sino Medical Sciences Technology Inc. (688108): Coronary business maintains high-speed growth, innovative single product for neurointervention is about to be certified.
The company's performance in the first half of 2024 meets expectations, with rapid growth in coronary artery business. The core product HT Supreme coronary stent is about to be approved in the US market. The future development trend of neurointervention business is promising, with heavyweight products.
Express News | Star market closing review: SSE Science and Technology Innovation Board 50 Index fell 0.40%, semiconductor sector showed mixed gains and losses.
Express News | Sino Medical Sciences Technology Inc.: the product has obtained a registration certificate in Hong Kong
sino medical sciences technology inc. (688108): The H1 performance meets expectations, waiting for the mass production of new products.
Event: The company released the 2024 interim report, with a revenue of 0.21 billion yuan for 2024H1 (+32.5%), and a net income attributable to the parent company of 0.008 billion yuan (+125.9%), achieving a turnaround from loss to profit; among which, 2024
No Data
No Data